Editorial abstract cover illustrating Dubai Essential Drug List (DEDL): How to Build the Evidence for a Formulary Listing
    Market Research

    Which Dubai list are you actually filing for? — A Dubai Essential Drug List formulary submission, list by list

    S
    Sarah ChenGlobal Research Manager
    17 Oct 2026
    9 min
    United Arab Emirates
    Dubai Essential Drug ListFormulary SubmissionDubai Drug CodeEssential Benefits PlanUnited Arab EmiratesMarket AccessPrimary ResearchReal-World Evidence
    Share:

    A Dubai Essential Drug List formulary submission asks three questions. Will the product get a Dubai Drug Code? Will a formulary restrict it? Will a Dubai plan pay? Official pages do not publish a list named DEDL. Read this with the healthcare market research hub. The federal pricing handover is on the EDE takeover briefing.

    What this submission is

    It is the evidence pack for a code, a formulary rule and a payer. Grand View Research, IMARC and IQVIA sell national outlooks. Those pages do not say which Dubai list the forecast is using.

    Do not plan to a quarterly “DEDL committee.” The public record cited here does not name one. It names a weekly code release, dated insurance circulars, and a facility list a committee may create (GC 12/2018; GC 03/2024; DHA Pharmacy Guidelines 2021).

    Which published lists sit behind the name

    Four lists are easy to collapse into one word. They are not one list.

    The Dubai Drug Code is the list of drugs registered with DHA Pharmacy Services. Each code includes route, form, pack size, price and source (GC 12/2018). eClaimLink still publishes that set (eClaimLink). A code identifies the SKU on a claim. It is not a promise that the Essential Benefits Plan will pay.

    The Essential Benefits Plan restricts drugs to formulary products where a formulary exists (GC 03/2024). That is an insurance rule, not a hospital list.

    The 2025 National Essential Medicines List is federal. EDE Chairman Decision No. 47 of 2025, dated 19 June 2025, adopted it (EDE legislations; NEML attachment; DHA-hosted Decision 47/2025). WHO posted an English file on 3 June 2026 (WHO). A molecule can sit on that list and still lack a Dubai code.

    A facility formulary is the list a hospital or clinic allows. DHA’s 2021 Pharmacy Guidelines say a multidisciplinary committee may create it, and that the medication-management system is reviewed at least once within 24 months (DHA Pharmacy Guidelines 2021). That review is not an emirate-wide quarterly vote.

    Four published Dubai and UAE medicine lists: Dubai Drug Code, Essential Benefits Plan formulary restriction, National Essential Medicines List, and facility formulary
    Four published layers a 2026 Dubai Essential Drug List formulary submission must keep separate: weekly DDC, EBP formulary restriction, 2025 NEML, and a facility formulary.

    What the Essential Benefits Plan pays

    Law No. 11 of 2013 applies across Dubai, including free zones such as DIFC. DHA approves packages, prices and co-insurance (Law 11/2013). Employers, including free-zone employers, must cover employees. Sponsors cover dependents. Dubai citizens and government employees are eligible under Enaya (Dubai.ae). The UNDP investment case describes Dubai’s Saada programme beside Abu Dhabi’s Thiqa programme (UNDP).

    Only Participating Insurers may sell the Essential Benefits Plan to residents earning AED 4,000 or less a month (ISAHD; ISAHD Employer Pack). GC 06/2024 named twenty of those insurers for 1 January 2025 to 31 December 2025 (GC 06/2024). That roster is a 2025 permit. Do not treat it as permanent.

    PD 01/2021 set the medicines line at AED 1,500 a year, including coinsurance (PD 01/2021). From 1 January 2025 the cap is AED 2,500, including coinsurance, with 30% per prescription and a formulary restriction (GC 03/2024). The same circular sets an Index Rate of AED 550–750 per member per year, plus or minus AED 25, and an annual aggregate claims limit of AED 150,000. On 7 October 2025, new Policy Directives revoked and replaced named earlier circulars (GC 05-2025). A 2026 brief writes to the Dubai Health Insurance Corporation as well as Pharmacy Services.

    Bar chart of the Essential Benefits Plan annual medicines cap: AED 1,500 in 2021 and AED 2,500 from 1 January 2025
    Essential Benefits Plan annual medicines cap, including coinsurance: AED 1,500 in PD 01/2021; AED 2,500 from 1 January 2025 under GC 03/2024.

    How a product gets a code

    The company files a registration form, a MOH certificate or a receipt, and an invoice with cost and selling prices. Updates release every Monday. Utilization starts on Thursday (eClaimLink DDC registration; GC 12/2018).

    On 5 January 2026, MOHAP transferred 44 core services to the Emirates Drug Establishment, including individual-product re-pricing and price lists (MOHAP, 5 January 2026). Federal Decree-Law No. 28 of 2023 was issued on 25 September 2023 and took effect on 30 September 2023 (UAE Legislation). Federal Decree-Law No. 38 of 2024 was issued on 1 October 2024 and took effect on 2 January 2025. Article 20 requires a Board-set price before marketing (UAE Legislation; FAOLEX Article 20). A pack that shows only an old ministry certificate, and never the EDE price, is incomplete. Re-pricing fees are AED 1,000 plus AED 500 (EDE re-pricing).

    Weekly Dubai Drug Code release: Monday list, Thursday utilization on eClaimLink
    Published DDC cadence on eClaimLink: updates every Monday; utilization starts on Thursday. A coding calendar, not a quarterly vote.

    WAM’s first-half 2026 note, to 30 June 2026, counts 942 product approvals, 20 pricing decisions and 2,030 inspection visits (WAM). Those are regulator counts. They are not a Dubai Drug Code count, and they are not a treated-patient forecast.

    A code is not a funded listing

    A Monday release lets a claim be coded. It does not put the product on an Essential Benefits formulary or on a facility list. Interview the wallet that will see the claim. The wider map sits on UAE pricing and reimbursement strategy. A Dubai answer is not a Thiqa answer. See Saudi Arabia and Kuwait.

    What local evidence payers publish

    Dubai’s circulars set a cap, a formulary restriction and a coding calendar. They do not publish a health-technology-assessment checklist. Abu Dhabi does.

    The April 2023 real-world evidence guideline applies when the file will go to the Department of Health for a regulatory, clinical or reimbursement decision. Following it does not guarantee a favourable decision (DOH RWE 2023).

    The June 2025 assessment guide makes local epidemiology mandatory. Real-world evidence may be requested in a class review. After the local setting, the Gulf is the next relevant one. Annual utilization under AED 10 million is out of scope, as is a per-patient cost under AED 100,000 a year (DOH HTA 2025). Federal Law No. 2 of 2019 does not allow health data from UAE services to be stored or transferred outside the country (DOH HTA). The managed-entry policy says the department may ask for more data, and the company has no access to patient-confidential data (DOH managed entry).

    What Abu Dhabi DOH has published on local epidemiology and real-world evidence versus what Dubai insurance circulars publish
    Abu Dhabi’s June 2025 HTA guide asks for local epidemiology and may request real-world evidence. Dubai’s circulars set an EBP cap and a formulary restriction.

    The last official national survey put adult diabetes at 11.8% in 2017–2018, down from 18.9% in 2010 (MOHAP National Health Survey; UNDP). That is not a 2026 Dubai treated share. FCSC puts the 2024 population at about 11.29 million, up 5.7% from 10.68 million, across about 200 nationalities (FCSC). Do not turn that residency count into patients on one SKU.

    What the study should measure

    Name the list the model uses. Then separate the code, the insurance rule and the facility stock.

    WorkstreamDecision it answersWhat the published record already showsWhat to commission
    List identityWhich list the forecast is usingDDC is every drug registered with DHA Pharmacy Services; EBP drugs are restricted to formulary products; EDE adopted a 2025 NEML (GC 12/2018; GC 03/2024; EDE Decision 47/2025)A four-list map for the SKU, not a single “DEDL” cell
    DDC codingWhether payers can even code the claimPharma companies file to DHA Pharmacy Services; updates release Monday and go live Thursday (eClaimLink DDC registration)Certificate, invoice and the next Monday slot
    EBP versus enhancedWhich wallet funds the scriptEBP medicines cap is AED 2,500 including coinsurance from 1 January 2025; 30% per prescription; no cover above the cap (GC 03/2024)Separate PI and enhanced-plan interviews
    Treated-patient shareWho is already on an analogNational adult diabetes was 11.8% in the last official survey — a prevalence, not a Dubai treated share (MOHAP National Health Survey)Anonymous PRFs, new versus continuing, by cover type
    Local RWEWhat a UAE payer will accept beside the RCTDOH’s RWE guideline applies when the outcome will be submitted to DOH for reimbursement decisions; the June 2025 HTA guide may request RWE in class reviews (DOH RWE 2023; DOH HTA 2025)A local epidemiology and analog-outcomes file, with data-residency rules stated
    Checklist of seven Dubai Essential Drug List formulary submission research workstreams
    Seven workstreams for a Dubai Essential Drug List formulary submission: list identity, DDC coding, EBP versus enhanced wallet, treated share, local RWE, budget impact, and facility formulary.

    Commission anonymous prescribing diaries for new and continuing patients, by cover type. Ask what the payer already spends inside and above the AED 2,500 medicines cap. A budget that prices only the new invoice, and ignores the cap and the 30% coinsurance, answers the wrong question.

    How to commission the study

    Name the SKU, the Monday release you are aiming at, and whether the script sits on the Essential Benefits Plan or an enhanced plan. State the data-residency rule before recruitment. Report share of treated patients, not a national market-size total.

    How to brief BioNixus

    BioNixus is a primary market research firm for pharmaceutical, medical device and healthcare companies. It was founded in 2012. It has served 118 clients in 48 countries. It has run 127 studies so far in 2026. It works with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East. Custom studies are usually priced at $10k–$60k. Leadership offices are in Sheridan, Wyoming, London EC1V 2NX, and Sheikh Zayed, Giza. There are a field office for UAE in Dubai, a partner office for KSA in Al Khobar, and a field office for Kuwait in Salmiya. São Paulo is a field office for LATAM. Work in Latin America is covered today from the US office with local consultants.

    The line “Guaranteed in writing” covers scope, timing, replacement of respondents who do not qualify, the minimum sample, re-fielding if that sample is missed, and a credited pilot. It does not cover what the interviews will find. BioNixus has 40 client reviews.

    Use the contact form or email admin@bionixus.com.

    References

    1. Government of Dubai. Law No. (11) of 2013 Concerning Health Insurance in the Emirate of Dubai. DHA approves packages, prices and co-insurance; cover is mandatory, including free zones such as DIFC. Source (accessed 17 October 2026).
    2. Dubai.ae. Health Insurance. Law No. 11 of 2013 makes cover mandatory for employers, including free zones, and for sponsors’ dependents; Dubai citizens and government employees are eligible under Enaya. Source (accessed 17 October 2026).
    3. DHA / ISAHD. GC 12/2018, The Dubai Drug Code (DDC) List and eClaimLink System. Weekly Monday release; Thursday utilization. Each code includes route, form, pack size, price and source. Source (accessed 17 October 2026).
    4. DHA / ISAHD. GC 03/2024 (23 July 2024). From 1 January 2025 the EBP medicines cap is AED 2,500 including coinsurance; 30% per prescription; restricted to formulary products where available. Source (accessed 17 October 2026).
    5. DHA / ISAHD. PD 01/2021 (21 November 2021). Previous EBP medicines cap AED 1,500 including coinsurance; same 30% coinsurance and formulary restriction. Source (accessed 17 October 2026).
    6. DHA / ISAHD. GC 06/2024. Twenty Participating Insurers permitted to sell the EBP to the low-salary band from 1 January 2025 to 31 December 2025. Source (accessed 17 October 2026).
    7. ISAHD. DHA Participating Insurers Results. The EBP is the DHA minimum; only Participating Insurers may sell it to residents earning AED 4,000 or less per month. Source (accessed 17 October 2026).
    8. ISAHD. Employer Information Pack v5.0 (1 July 2015). Confirms the EBP floor and the AED 4,000 salary band. Source (accessed 17 October 2026).
    9. DHIC / ISAHD. GC 05-2025 (7 October 2025). New Policy Directives revoke and replace named earlier ISAHD circulars. Source (accessed 17 October 2026).
    10. DHA Health Regulation Sector. Pharmacy Guidelines, Version 1 (2021). A facility formulary may be created by a multidisciplinary committee and reviewed at least once within 24 months. Source (accessed 17 October 2026).
    11. Emirates Drug Establishment. Legislations page. Lists Decree-Law 28/2023 and Chairman Decision 47/2025 adopting the NEML on 19 June 2025. Source (accessed 17 October 2026).
    12. EDE. Attachment to Chairman Decision No. (47) of 2025. 2025 National Essential Medicines List by therapeutic class. Source (accessed 17 October 2026).
    13. DHA-hosted copy of EDE Chairman Decision No. (47) of 2025, dated 19 June 2025, with the 2025 UAE NEML attached. Source (accessed 17 October 2026).
    14. World Health Organization. United Arab Emirates: National Essential Medicine List 2025 (English). Posted 3 June 2026. Source (accessed 17 October 2026).
    15. MoHAP. Transfer of 44 core services to EDE, 5 January 2026, including individual-product re-pricing and regulated-medicine price lists. Source (accessed 17 October 2026).
    16. UAE Legislation. Federal Decree-Law No. 28 of 2023 establishing the UAE Drug Corporation. Effective 30 September 2023. Source (accessed 17 October 2026).
    17. UAE Legislation. Federal Decree-Law No. 38 of 2024. Issued 1 October 2024; effective 2 January 2025. Source (accessed 17 October 2026).
    18. FAOLEX English text. Federal Decree-Law No. (38) of 2024. Article 20: marketing a medical product requires a specific Board-set price. Source (accessed 17 October 2026).
    19. DOH Abu Dhabi. RWE guideline, April 2023 (DOH/GL/RWD_RWE/V1). Applies when the outcome will be submitted to DOH for regulatory, clinical or reimbursement decisions. Compliance does not guarantee a favourable decision. Source (accessed 17 October 2026).
    20. DOH Abu Dhabi. HTA Guidelines, June 2025. Local epidemiology is mandatory; RWE may be requested in class reviews. Out of scope includes utilization under AED 10 million a year. Notes Federal Law No. (2) of 2019 on ICT in healthcare. Source (accessed 17 October 2026).
    21. DOH Abu Dhabi. Managed Entry / Risk Sharing policy. DOH may request more data; the company has no access to patient-confidential data. Source (accessed 17 October 2026).
    22. FCSC. Unified UAE Numbers (English), December 2025. Population about 11.29 million in 2024, up 5.7% from 10.68 million in 2023; about 200 nationalities. Source (accessed 17 October 2026).
    23. MoHAP. National Health Survey. Adult diabetes 11.8% (2017–2018 STEPS-style figure), down from 18.9% in 2010. Not a 2026 treated share. Source (accessed 17 October 2026).
    24. UNDP / Gulf Health Council. UAE NCD investment case. Notes the 11.8% diabetes figure and Dubai’s Saada and Abu Dhabi’s Thiqa programmes. Source (accessed 17 October 2026).
    25. WAM. EDE H1 2026, 22 September 2026. To 30 June 2026: 942 product approvals; 20 pricing decisions; 2,030 inspection visits. Source (accessed 17 October 2026).
    26. EDE. Re-Pricing of a Single Medical Product. Country-of-origin certificate plus Gulf and European references; fees AED 1,000 plus AED 500. Source (accessed 17 October 2026).
    27. Grand View Research. United Arab Emirates pharmaceutical market outlook pages. Syndicated category sizing, not a primary-research file on a Dubai Essential Drug List formulary submission. (accessed 17 October 2026).
    28. IMARC Group. UAE pharmaceutical market report pages. Syndicated market-size commentary that often occupies “UAE pharmaceutical market” queries. (accessed 17 October 2026).
    29. IQVIA. UAE and Middle East pharmaceutical audit and market commentary. Useful for national audit context; it does not replace a Dubai Drug Code, Essential Benefits Plan or payer-listing primary-research file. (accessed 17 October 2026).

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    What is a Dubai Essential Drug List formulary submission?
    The evidence pack that asks whether a product will get a Dubai Drug Code, sit on a formulary and be paid for in Dubai. Official pages do not publish a list named DEDL.
    Does DHA publish a list officially named the Dubai Essential Drug List?
    No. The published pieces are a weekly Dubai Drug Code, an Essential Benefits Plan that restricts drugs to formulary products, a 2025 national essential-medicines list, and facility formularies.
    How often is the Dubai Drug Code updated?
    DHA Pharmacy Services releases updates every Monday. Utilization starts on Thursday. That is a coding calendar, not a quarterly committee.
    What does the Essential Benefits Plan pay for medicines?
    From 1 January 2025 the medicines cap is AED 2,500 a year, including coinsurance, with 30% per prescription. The earlier cap was AED 1,500. Cover above the cap is not in the basic plan. Only Participating Insurers may sell the plan to residents earning AED 4,000 or less a month.
    Is a Dubai Drug Code the same as reimbursement?
    No. A code identifies the pack and already includes a price. Payment still depends on the plan’s formulary rule and on whether a facility stocks the product. A federal public price is a third layer.
    What local evidence do UAE payers ask for?
    Abu Dhabi’s 2023 real-world evidence guide and June 2025 assessment guide ask for local epidemiology. Real-world evidence may be requested. Dubai’s circulars set a cap and a formulary restriction. Following the guides does not guarantee a favourable decision.
    Why commission BioNixus for a Dubai formulary brief?
    Custom studies run from the Dubai field office, with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East, usually at $10k–$60k. Guaranteed in writing covers scope and sample. It does not cover what the interviews will find.

    Expert Consultation

    Planning a Dubai Essential Drug List formulary submission?

    Tell us which Dubai list the decision is about. BioNixus scopes the study around that list. Custom work is usually $10k–$60k.

    Talk to BioNixus
    S

    Research Author

    Sarah Chen

    Global Research Manager

    Related Articles

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.

    Syndicated Saudi diabetes reports size the category. They do not show which hospital is switching. Here is what primary research still has to answer.

    Read article
    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant
    Healthcare Market Research
    UAE11 Nov 2026

    ADCAN Pharma and M42 Want to Make the UAE an Oncology Supply Hub. The First Step Is a Pack, Not a Plant

    ADCAN Pharma and M42 signed an MoU on UAE oncology manufacturing, an ADC registration and IROS clinical trials. What is confirmed and what to research.

    Read article
    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now
    Healthcare Market Research
    UAE10 Nov 2026

    The UAE Has Cleared Lilly's Foundayo Pill for Type 2 Diabetes. The Harder Questions Start Now

    The UAE approved Lilly's oral GLP-1 Foundayo for type 2 diabetes on 6 Nov 2026. What is confirmed, what is not, and what launch teams should research.

    Read article
    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One
    Healthcare Market Research
    Saudi Arabia5 Nov 2026

    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One

    Avalon Pharma licensed a generic Mounjaro KwikPen (tirzepatide) from OneSource for Saudi Arabia and MENA. What it means for GLP-1 and obesity teams.

    Read article
    EVA Pharma's TriGutirek XR Puts a Triple Diabetes Tablet into Saudi Pharmacies. Here Is What Market Access Teams Should Check Next
    Healthcare Market Research
    Saudi Arabia4 Nov 2026

    EVA Pharma's TriGutirek XR Puts a Triple Diabetes Tablet into Saudi Pharmacies. Here Is What Market Access Teams Should Check Next

    EVA Pharma's TriGutirek XR (empagliflozin/linagliptin/metformin XR) is described as the first triple FDC of these actives approved in Saudi Arabia. Cigalah and United Pharmacies deals, SFDA listing no

    Read article

    Planning research in United Arab Emirates?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.